Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
By now, we’ve had a chance to brush up on the Hanta virus, esp. the Andes variety which caused a mini-epidemic on the arctic cruise ship MV Hondius. Named after Hantaan, the river in South Korea where the disease first emerged, we give credit to Dr. Ho Wang Lee, the Continue reading HANTA & WHAT’S NEXT
Quick: What do you associate with the abbreviation ‘TCR’? Does your immunology-trained mind automatically default to ‘T-cell receptor’? Or is your first guess ‘Tissue Cross Reactivity? Our neural networks can deal with ambivalence and will make the right associations, eventually. Language is imprecise by design and allows for wobble. Things Continue reading OFF-TARGET ANTIBODIES
A recent Nature Review Drug Discovery article caught our attention, a review of TIGIT as an IO target and the failed Phase 3 study of tiragolumab which is the TIGIT inhibitor from Roche.[1] The science writer interviewed a group of insiders that had a lead role in the development of Continue reading The Tiragolumab Saga & Tifacogin Flash-Backs